Alnylam Pharmaceuticals (ALNY) Stock Falls As Q3 Earnings Lean On Tax Gain
Alnylam Pharmaceuticals (ALNY) Stock Falls As Q3 Earnings Lean On Tax Gain Simply Wall St
Covered in this story
Analyst targets on Alnylam Pharmaceuticals
- Freedom Broker: $174 → $350 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ALNY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alnylam Pharmaceuticals →Dalsna Finance is currently tracking 50 stories mentioning Alnylam Pharmaceuticals, the earliest published 10 Jul 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.